|
Volumn 33, Issue 2, 2008, Pages 38-42
|
The new renin antagonist: Aliskiren
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALISKIREN;
AMLODIPINE;
ANGIOTENSIN;
ATORVASTATIN;
CYTOCHROME P450 3A4;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
FUROSEMIDE;
HYDROCHLOROTHIAZIDE;
IRBESARTAN;
KETOCONAZOLE;
PLACEBO;
POTASSIUM;
RAMIPRIL;
RENIN;
VALSARTAN;
WARFARIN;
ANTIHYPERTENSIVE ACTIVITY;
ARTICLE;
BLOOD PRESSURE REGULATION;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
COMORBIDITY;
DIARRHEA;
DIASTOLIC BLOOD PRESSURE;
DRUG ABSORPTION;
DRUG CONTRAINDICATION;
DRUG COST;
DRUG DOSE COMPARISON;
DRUG DOSE ESCALATION;
DRUG DOSE INCREASE;
DRUG DOSE TITRATION;
DRUG EFFICACY;
DRUG EXCRETION;
DRUG METABOLISM;
DRUG SAFETY;
HUMAN;
HYPERTENSION;
MONOTHERAPY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OBESITY;
PATIENT COMPLIANCE;
PATIENT COUNSELING;
PLASMA RENIN ACTIVITY;
POTASSIUM BLOOD LEVEL;
PREGNANCY;
REBOUND;
RENIN RELEASE;
SIDE EFFECT;
SYSTOLIC BLOOD PRESSURE;
WITHDRAWAL SYNDROME;
|
EID: 48249087717
PISSN: 01484818
EISSN: None
Source Type: Trade Journal
DOI: None Document Type: Article |
Times cited : (1)
|
References (8)
|